Cargando…

A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo

Macroautophagy/autophagy is an evolutionarily conserved catabolic pathway whose modulation has been linked to diverse disease states, including age-associated disorders. Conventional and conditional whole-body knockout mouse models of key autophagy genes display perinatal death and lethal neurotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassidy, Liam D., Young, Andrew RJ., Pérez-Mancera, Pedro A., Nimmervoll, Birgit, Jaulim, Adil, Chen, Hung-Chang, McIntyre, Dominick J. O., Brais, Rebecca, Ricketts, Thomas, Pacey, Simon, De La Roche, Maike, Gilbertson, Richard J., Rubinsztein, David C., Narita, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103714/
https://www.ncbi.nlm.nih.gov/pubmed/29999454
http://dx.doi.org/10.1080/15548627.2018.1458172
Descripción
Sumario:Macroautophagy/autophagy is an evolutionarily conserved catabolic pathway whose modulation has been linked to diverse disease states, including age-associated disorders. Conventional and conditional whole-body knockout mouse models of key autophagy genes display perinatal death and lethal neurotoxicity, respectively, limiting their applications for in vivo studies. Here, we have developed an inducible shRNA mouse model targeting Atg5, allowing us to dynamically inhibit autophagy in vivo, termed ATG5i mice. The lack of brain-associated shRNA expression in this model circumvents the lethal phenotypes associated with complete autophagy knockouts. We show that ATG5i mice recapitulate many of the previously described phenotypes of tissue-specific knockouts. While restoration of autophagy in the liver rescues hepatomegaly and other pathologies associated with autophagy deficiency, this coincides with the development of hepatic fibrosis. These results highlight the need to consider the potential side effects of systemic anti-autophagy therapies.